UNSPSC 51401524: Fludiazepam

This classification denotes a benzodiazepine with the molecular formula C16H12ClFN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7F64A2K16Z, chemically known as 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-methyl-2h-1,4-benzodiazepin-2-one but generally known as fludiazepam, which bears US NIH Compound Identifier 3369. European Medicines Agency schedules Fludiazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07681MIG.

UNSPSC 51401524 Fludiazepam is a Commodity code for a specific pharmaceutical product, but the single recent state and local opportunity posted under this code does not involve fludiazepam procurement. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually—a public health initiative unrelated to the code's nominal scope. The mismatch suggests either a misclassification by the issuing body or limited recent activity specifically tagged to fludiazepam at the state and local level. State and local procurement under this code does not show a clear pattern of actual buying activity in the available recent record.

The single opportunity identified comes from Seminole County, Florida, a county health department, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The IFB closed July 26, 2023, with vendors required to include all shipping and delivery costs, maintain workers' compensation and general liability insurance, and comply with E-Verify and drug-free workplace certification. The contract structure includes an initial two-year term with a one-year renewal option and potential FEMA funding. Without additional recent solicitations under this code across other jurisdictions or states, the current market signal is minimal—pursue only if your firm has existing fludiazepam supply relationships with county or municipal health systems and can verify active demand separate from this naloxone-focused opportunity.